Retatrutide
GLP-1 / GIP / Glucagon Triple Agonist
Retatrutide is a next-generation triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. It represents one of the most potent investigational compounds for metabolic research, demonstrating significant effects on body weight and glucose regulation in preclinical and early clinical studies.
Available Sizes
Mechanism of Action
Acts on three distinct receptor pathways: GLP-1 receptors to reduce appetite and slow gastric emptying, GIP receptors to enhance insulin secretion, and glucagon receptors to increase energy expenditure. This triple mechanism produces synergistic metabolic effects beyond single or dual agonists.
Research Highlights
- Triple receptor agonism (GLP-1, GIP, Glucagon)
- Significant reductions in body weight observed in Phase 2 trials
- Improved fasting glucose and insulin sensitivity markers
- Favorable lipid profile changes in research subjects
Product Specifications
Research Use Only. Retatrutide is sold exclusively for in vitro research and laboratory use. It is not intended for human or veterinary consumption, therapeutic use, or any other purpose. By purchasing, you confirm you are a qualified researcher and will use this compound in compliance with all applicable laws.
